Market Closed -
Nasdaq
04:00:00 2024-05-10 pm EDT
|
5-day change
|
1st Jan Change
|
2.34
USD
|
-7.51%
|
|
-8.95%
|
+32.20%
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
1,002
|
448.2
|
141.1
|
330.9
|
437.6
|
-
|
-
|
Enterprise Value (EV)
1 |
750.9
|
299.1
|
91.21
|
227.5
|
335.3
|
293.8
|
83
|
P/E ratio
|
-7.81
x
|
-2.51
x
|
-0.6
x
|
-1.84
x
|
-5.76
x
|
-4.92
x
|
-6.28
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
-
|
-
|
56.4
x
|
21.4
x
|
47.5
x
|
86
x
|
8.54
x
|
EV / Revenue
|
-
|
-
|
36.5
x
|
14.7
x
|
36.4
x
|
57.7
x
|
1.62
x
|
EV / EBITDA
|
-17.5
x
|
-1.73
x
|
-0.73
x
|
-3.2
x
|
-4.97
x
|
-3.23
x
|
2.4
x
|
EV / FCF
|
-24.4
x
|
-2.26
x
|
-0.84
x
|
-2.96
x
|
-5.4
x
|
-3.97
x
|
-0.9
x
|
FCF Yield
|
-4.1%
|
-44.2%
|
-120%
|
-33.8%
|
-18.5%
|
-25.2%
|
-111%
|
Price to Book
|
3.99
x
|
4.7
x
|
105
x
|
4.42
x
|
46.8
x
|
-6.5
x
|
-
|
Nbr of stocks (in thousands)
|
37,761
|
38,474
|
62,442
|
186,960
|
187,018
|
-
|
-
|
Reference price
2 |
26.54
|
11.65
|
2.260
|
1.770
|
2.340
|
2.340
|
2.340
|
Announcement Date
|
3/3/21
|
3/31/22
|
3/28/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
-
|
-
|
2.502
|
15.45
|
9.217
|
5.09
|
51.25
|
EBITDA
1 |
-42.99
|
-172.8
|
-124.9
|
-71.07
|
-67.48
|
-90.9
|
34.54
|
EBIT
1 |
-43
|
-173.3
|
-162.4
|
-72.44
|
-74.63
|
-91.2
|
-79.79
|
Operating Margin
|
-
|
-
|
-6,492.69%
|
-468.83%
|
-809.73%
|
-1,791.62%
|
-155.7%
|
Earnings before Tax (EBT)
1 |
-60.01
|
-174.5
|
-166
|
-111.6
|
-77.86
|
-94.78
|
-75.55
|
Net income
1 |
-60.01
|
-174.5
|
-166
|
-111.6
|
-77.86
|
-92.9
|
-69.45
|
Net margin
|
-
|
-
|
-6,635.25%
|
-722.06%
|
-844.81%
|
-1,825.16%
|
-135.52%
|
EPS
2 |
-3.400
|
-4.640
|
-3.780
|
-0.9600
|
-0.4060
|
-0.4756
|
-0.3725
|
Free Cash Flow
1 |
-30.81
|
-132.3
|
-109
|
-76.89
|
-62.07
|
-73.98
|
-91.77
|
FCF margin
|
-
|
-
|
-4,356.87%
|
-497.62%
|
-673.48%
|
-1,453.46%
|
-179.09%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
3/3/21
|
3/31/22
|
3/28/23
|
3/19/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
-
|
-
|
-
|
-
|
-
|
2.502
|
4.706
|
2.395
|
4.746
|
3.604
|
2.305
|
2.31
|
2.295
|
2.315
|
3.101
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-50.68
|
-49.72
|
-49.27
|
-32.98
|
-25.07
|
-55.12
|
-16.56
|
-23.38
|
-15.63
|
-16.25
|
-18.54
|
-19.19
|
-19.74
|
-19.52
|
-22.4
|
Operating Margin
|
-
|
-
|
-
|
-
|
-
|
-2,203.04%
|
-351.87%
|
-976.37%
|
-329.41%
|
-450.78%
|
-804.17%
|
-830.67%
|
-859.84%
|
-843.16%
|
-722.28%
|
Earnings before Tax (EBT)
1 |
-51.19
|
-50.39
|
-50.11
|
-33.87
|
-26.31
|
-55.72
|
-17.62
|
-24.6
|
-117.1
|
47.74
|
-19.27
|
-19.76
|
-20.18
|
-20.16
|
-22.42
|
Net income
1 |
-51.19
|
-50.39
|
-50.11
|
-33.87
|
-26.31
|
-55.72
|
-17.62
|
-24.6
|
-117.1
|
47.74
|
-19.27
|
-19.76
|
-20.18
|
-20.16
|
-22.42
|
Net margin
|
-
|
-
|
-
|
-
|
-
|
-2,227.14%
|
-374.46%
|
-1,027.06%
|
-2,467.07%
|
1,324.67%
|
-835.72%
|
-855.31%
|
-879.16%
|
-870.48%
|
-722.87%
|
EPS
2 |
-1.350
|
-1.320
|
-1.310
|
-0.8400
|
-0.6400
|
-0.9900
|
-0.2800
|
-0.3800
|
-0.9300
|
0.9200
|
-0.1111
|
-0.1156
|
-0.1167
|
-0.1133
|
-0.1100
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
11/10/21
|
3/31/22
|
5/16/22
|
8/11/22
|
11/8/22
|
3/28/23
|
5/11/23
|
8/14/23
|
11/14/23
|
3/19/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
251
|
149
|
49.9
|
103
|
102
|
144
|
355
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-30.8
|
-132
|
-109
|
-76.9
|
-62.1
|
-74
|
-91.8
|
ROE (net income / shareholders' equity)
|
-47.8%
|
-101%
|
-345%
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
2 |
6.650
|
2.480
|
0.0200
|
0.4000
|
0.0500
|
-0.3600
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.08
|
15.3
|
20.6
|
3.87
|
4.52
|
3.41
|
4.95
|
Capex / Sales
|
-
|
-
|
824.1%
|
25.04%
|
49.08%
|
67.05%
|
9.65%
|
Announcement Date
|
3/3/21
|
3/31/22
|
3/28/23
|
3/19/24
|
-
|
-
|
-
|
Last Close Price
2.34
USD Average target price
6.833
USD Spread / Average Target +192.02% Consensus |
1st Jan change
|
Capi.
|
---|
| +32.20% | 438M | | +17.96% | 44.96B | | +1.17% | 42.65B | | +48.77% | 41.85B | | -4.27% | 29.04B | | +11.42% | 26.08B | | -21.39% | 19.03B | | +4.86% | 12.75B | | +27.29% | 12.06B | | -3.50% | 11.75B |
Other Biotechnology & Medical Research
|